Mineralys Therapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Mineralys Therapeutics submitted its lead hypertension drug, lorundrostat, for FDA approval and bolstered its financial position with significant capital raises, despite continued net losses.
NASDAQ
10-K: Mineralys Therapeutics Reports Significant Losses in 2024, Focus Remains on Lorundrostat Development
Mineralys Therapeutics faces substantial net losses in 2024 while advancing its lead drug candidate, lorundrostat, through clinical trials targeting hypertension and related cardiorenal conditions.
NASDAQ
Mineralys Therapeutics' 10-K filing details its common stock structure, anti-takeover provisions, and ongoing clinical trials for lorundrostat.